Literature DB >> 20347270

Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention.

S M Francey1, B Nelson, A Thompson, A G Parker, M Kerr, C Macneil, R Fraser, F Hughes, K Crisp, S Harrigan, S J Wood, M Berk, P D McGorry.   

Abstract

In recent years, early intervention services have attempted to identify people with a first episode of psychosis as early as possible, reducing the duration of untreated psychosis and changing the timing of delivery of interventions. The logic of early intervention is based partly on accessing people in a more treatment responsive stage of illness in which psychosocial damage is less extensive, and partly on remediating a putatively active process of neuroprogression that leads to pathophysiological, symptomatic and structural changes, hence improving symptomatic and functional outcomes. However, as in other areas of health care, earlier identification of new patients may mean that different treatment approaches are indicated. The corollary of early detection is that the sequence and complexion of treatment strategies for first episode psychosis has been revaluated. Examples include the minimal effective dosage of antipsychotic medication and the content of psychosocial interventions. With the substantial reductions of DUP now seen in many early psychosis services, based on clinical staging and stepped care principles, it is even possible that the immediate introduction of antipsychotic medication may not be necessary for all first episode psychosis cases, but that potentially safer interventions, which may be more acceptable to many patients, such as comprehensive psychosocial intervention, may constitute effective treatment at least for a subgroup of patients. In this paper, we review this theoretical background and describe a randomised controlled trial currently underway at the Early Psychosis Prevention and Intervention Centre (EPPIC) in Melbourne designed to test outcomes for first episode psychosis patients in response to two different treatments: intensive psychosocial intervention plus antipsychotic medication versus intensive psychosocial intervention plus placebo. This is a theoretically and pragmatically novel study in that it will provide evidence as to whether intensive psychosocial intervention alone is sufficient for a subgroup of first episode psychosis patients in a specialised early intervention service, and provide a test of the heuristic clinical staging model. By experimentally manipulating duration of untreated psychosis, the study will also provide a methodologically strong test of the effect of delaying the introduction of antipsychotic medication, as well as helping to disentangle the effects of antipsychotic medications and the putative neurobiological processes associated with brain changes and symptom profiles in the early phase of psychotic disorders. The study has been carefully crafted to satisfy critical ethical demands in this challenging research domain. Crown Copyright (c) 2010. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20347270     DOI: 10.1016/j.schres.2010.02.1071

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  29 in total

Review 1.  The residential care alternative for the acutely psychotic patient.

Authors:  Pesach Lichtenberg
Journal:  Psychiatr Q       Date:  2011-12

Review 2.  Psychosis prediction and clinical utility in familial high-risk studies: selective review, synthesis, and implications for early detection and intervention.

Authors:  Jai L Shah; Neeraj Tandon; Matcheri S Keshavan
Journal:  Early Interv Psychiatry       Date:  2013-05-22       Impact factor: 2.732

3.  Diagnostic markers for schizophrenia: do we actually know what we're looking for?

Authors:  Stephen J Wood; Alison R Yung
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

Review 4.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

5.  Medication adherence in first episode psychosis: the role of pre-onset subthreshold symptoms.

Authors:  J-G Daneault; A Maraj; M Lepage; A Malla; N Schmitz; S N Iyer; R Joober; J L Shah
Journal:  Acta Psychiatr Scand       Date:  2019-04       Impact factor: 6.392

Review 6.  Antipsychotic medication for early episode schizophrenia.

Authors:  John Bola; Dennis Kao; Haluk Soydan
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

7.  Reduction in incidence of hospitalizations for psychotic episodes through early identification and intervention.

Authors:  William R McFarlane; Ezra Susser; Richard McCleary; Mary Verdi; Sarah Lynch; Deanna Williams; Ian W McKeague
Journal:  Psychiatr Serv       Date:  2014-10       Impact factor: 3.084

8.  Remission and recovery and their predictors in schizophrenia spectrum disorder: results from a 1-year follow-up naturalistic trial.

Authors:  Rebecca Schennach; Michael Riedel; Michael Obermeier; Markus Jäger; Max Schmauss; Gerd Laux; Herbert Pfeiffer; Dieter Naber; Lutz G Schmidt; Wolfgang Gaebel; Joachim Klosterkötter; Isabella Heuser; Wolfgang Maier; Matthias R Lemke; Eckart Rüther; Stefan Klingberg; Markus Gastpar; Florian Seemüller; Hans-Jürgen Möller
Journal:  Psychiatr Q       Date:  2012-06

Review 9.  Progress and Future Directions in Research on the Psychosis Prodrome: A Review for Clinicians.

Authors:  Kristen A Woodberry; Daniel I Shapiro; Caitlin Bryant; Larry J Seidman
Journal:  Harv Rev Psychiatry       Date:  2016 Mar-Apr       Impact factor: 3.732

10.  Early psychosis research at Orygen, The National Centre of Excellence in Youth Mental Health.

Authors:  S M Cotton; K M Filia; A Ratheesh; K Pennell; S Goldstone; P D McGorry
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-01       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.